STOCK TITAN

Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Simulations Plus, Inc. (NASDAQ: SLP), a leader in modeling software for pharmaceutical safety, will present at the Raymond James 44th Annual Institutional Investors Conference from March 5-8, 2023, in Orlando, Florida. CEO Shawn O’Connor is scheduled to speak on March 7, 2023, at 1:40 p.m. Eastern Time and will host one-on-one meetings. Interested parties can access a live webcast and presentation on the company's Investors page post-event. Attendance is by invitation only. Simulations Plus has been serving the biosimulation market for over 25 years, offering solutions for drug discovery and regulatory submissions.

Positive
  • None.
Negative
  • None.

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at the Raymond James & Associates’ 44th Annual Institutional Investors Conference, scheduled for March 5-8, 2023, at the JW Marriott Grande Lakes in Orlando, Florida.

Shawn O’Connor, chief executive officer, will present on Tuesday, March 7, 2023, at 1:40 p.m. Eastern Time. In addition, Mr. O’Connor will be available to host one-on-one meetings throughout the day. The live webcast and slide presentation will be available via this link and on the Investors page of the Simulations Plus website where it will also be available for replay after the event.

The conference is by invitation only, so to attend the conference or request a one-on-one meeting, please contact your Raymond James representative. For more information about the Raymond James Institutional Investors Conference, please visit the Raymond James website or contact Brian Siegel from Hayden IR at brian@haydenir.com.

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | LinkedIn.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report

Simulations Plus Investor Relations

Ms. Renee Bouche

661-723-7723

renee.bouche@simulations-plus.com

Hayden IR

Mr. Brian Siegel

(346) 396-8696

brian@haydenir.com

Source: Simulations Plus, Inc.

FAQ

When will Simulations Plus present at the Raymond James conference?

Simulations Plus will present at the Raymond James 44th Annual Institutional Investors Conference on March 7, 2023.

What time is the Simulations Plus presentation at the conference?

The Simulations Plus presentation is scheduled for 1:40 p.m. Eastern Time on March 7, 2023.

How can I access the Simulations Plus conference presentation?

The conference presentation will be available via a live webcast and on the company's Investors page after the event.

Where is the Raymond James Institutional Investors Conference being held?

The conference is being held at the JW Marriott Grande Lakes in Orlando, Florida.

Who is the CEO of Simulations Plus?

Shawn O’Connor is the CEO of Simulations Plus.

What is the focus of Simulations Plus's business?

Simulations Plus specializes in modeling and simulation software for pharmaceutical safety and efficacy.

Simulations Plus, Inc.

NASDAQ:SLP

SLP Rankings

SLP Latest News

SLP Stock Data

629.91M
16.42M
18.14%
77.89%
4.88%
Health Information Services
Services-computer Integrated Systems Design
Link
United States of America
LANCASTER